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Abstract: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the
betacoronavirus family, which causes COVID-19 disease. SARS-CoV-2 pathogenicity in humans leads
to increased mortality rates due to alterations of significant pathways, including some resulting in
exacerbated inflammatory responses linked to the “cytokine storm” and extensive lung pathology,
as well as being linked to a number of comorbidities. Our current study compared five SARS-CoV-2
sequences from different geographical regions to those from SARS, MERS and two cold viruses,
OC43 and 229E, to identify the presence of miR-like sequences. We identified seven key miRs,
which highlight considerable differences between the SARS-CoV-2 sequences, compared with the
other viruses. The level of conservation between the five SARS-CoV-2 sequences was identical but
poor compared with the other sequences, with SARS showing the highest degree of conservation.
This decrease in similarity could result in reduced levels of transcriptional control, as well as a change
in the physiological effect of the virus and associated host-pathogen responses. MERS and the milder
symptom viruses showed greater differences and even significant sequence gaps. This divergence
away from the SARS-CoV-2 sequences broadly mirrors the phylogenetic relationships obtained
from the whole-genome alignments. Therefore, patterns of mutation, occurring during sequence
divergence from the longer established human viruses to the more recent ones, may have led to
the emergence of sequence motifs that can be related directly to the pathogenicity of SARS-CoV-2.
Importantly, we identified 7 key-microRNAs (miRs 8066, 5197, 3611, 3934-3p, 1307-3p, 3691-3p,
1468-5p) with significant links to KEGG pathways linked to viral pathogenicity and host responses.
According to Bioproject data (PRJNA615032), SARS-CoV-2 mediated transcriptomic alterations were
similar to the target pathways of the selected 7 miRs identified in our study. This mechanism could
have considerable significance in determining the symptom spectrum of future potential pandemics.
KEGG pathway analysis revealed a number of critical pathways linked to the seven identified
miRs that may provide insight into the interplay between the virus and comorbidities. Based on
our reported findings, miRNAs may constitute potential and effective therapeutic approaches in
COVID-19 and its pathological consequences.
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1. Introduction
The emergence of SARS-coronavirus-2 (SARS-CoV-2), which causes coronavirus-mediated
disease 2019, or COVID-19, has now spread pandemically, resulting in a serious global health
crisis. Coronaviruses are positive-single stranded RNA (+ssRNA) zoonotic viruses with a ~30 kb
genome (approx). The coronavirus subfamily is divided into four genera: α, β, γ, and δ, based on
serotype and genome features. The genome of a typical CoV codes for at least 6 different open reading
frames (ORFs), which have variations based on the CoV type 4. Some ORFs encode non-structural
proteins while others code for structural proteins required for viral replication and pathogenesis.
Structural proteins include the spike (S) glycoprotein, which has various roles in SARS-CoV based on
sequence analysis and might share similar viral genomic and transcriptomic complexity. Other proteins
include matrix (M) protein, small envelope (E) protein, and nucleocapsid (N) protein for virus entrance
and spread [1]. SARS-CoV-2 infections mainly target the lungs with respect to other viral infections,
which begin with upper respiratory tract symptoms. However, it is obvious that an important
differentiating feature of the current SARS-CoV-2 infection is that it does not follow regular viral
lower respiratory infection pathways. There are a wide variety of clinical symptoms presented by
SARS-CoV-2 infection. Mainly (otherwise unexplained) fever and a failure to breathe fully are the
most frequent symptoms, with non-productive cough, sneezing, sudden loss of smell and/or taste,
pain in the chest cavity (mostly anteriorly), headache and prominent muscle ache, abdominal pain
with diarrhoea, and neurological symptoms with facial nerve involvement [2]. Patients are generally
referred to hospital when fever does not subside for 2 to 3 days, or respiratory effort gets harder. Clinical
observation indicates that elderly patients present more unexplained fever for 3 days, in contrast to
younger patients who present with difficulty in breathing without fever. In addition, the current
lack of successful therapeutic intervention strategies to prevent the disease, or overcome serious
mortality rates as a result of difficult lung pathophysiology mediated by SARS-CoV-2 infection, requires
clarification of the molecular aetiology behind the mild or severe conditions of the disease. Increasing
mortality rates are the major obstacle in the management of the disease in existing healthcare systems,
which have insufficient numbers of intensive care units. Clinically, the initiation of acute respiratory
distress syndrome (ARDS), which is the predominant severe pathology, leads to diffuse alveolar
damage (DAD). In addition, the presence of a cytokine storm, the excessive and uncontrolled release
of pro-inflammatory cytokines such as IL-6, TNFα, IL-1β, IL-8, and IL2R, is associated with ARDS,
hypercoagulation and increased erythematosus sedimentation rate (ESR) [3]. SARS-CoV-2, as well
as other viruses, leads to pathophysiological problems in the host cells, and alters the expression of
a number of genes. Thus, clarification of molecular regulators on human cells is important to evaluate
molecular mechanisms.
MicroRNAs (miRs) are non-coding RNAs of length approximately 20–22 nucleotides; they post-
transcriptionally regulate gene expression by binding to the 3′-untranslated regions of target mRNAs,
leading to degradation or translational inhibition. Each miR can target hundreds of mRNAs within
a given cell type, and a single mRNA is often the target of multiple miRs, and thus over half of the
human transcriptome is predicted to be under miR regulation, embedding this post-transcriptional
control pathway within nearly every biological process [4,5]. Virally expressed miRs have recently
been discovered, especially in viruses with DNA genomes. The best-known viral miRs are found
mostly in herpesvirus families, where they enhance bilateral crosstalk between viral pathogenesis and
host response mechanisms. Additionally, it has been shown that different virus families such as delta
bovine leukaemia virus and foamy retroviruses could encode miRs [6]. As previously shown, viral
miRs are critical in the immune evasion mechanisms, affecting host immunity-related gene regulation
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networks. This bilateral effect results in a rapid increase during the virus resistance against host
defence mechanisms and leads to their survival in host cells [7]. The scope of miR generation from
ssRNA viral genomes has been controversial, mainly due to the potentially deleterious effect of ssRNA
viral genome cleavage into pre-/pri-miRs, making it unavailable for packaging into new virus particles.
However, predictive studies on RNA viral genomes reveal RNA structures, which are conceivable
Drosha and Dicer substrates. One of the well-described annotations was performed for HIV to define
HIV-1 TAR RNA, a 59-nt long sequence that could generate a stem-loop structure similar to the pre-miR
structure [8]. The identified numbers of viral miRs are not as many as for other organisms. One of the
reasons for this is that viral miRs, due to their cytoplasmic location in host cells, render interaction
with nuclear miR biogenesis elements of the host cells. Another hypothesis is that the cleavage of
the viral RNA genome could generate miRs [9]. According to data obtained using in silico screening,
there are fewer identified virus miRs compared with other species, and their functional roles in host
cells are not well described. Therefore, greater effort is required to identify novel virally encoded
miRs and to predict their host targets. Conversely, host cell miRs may alter the biological effect of the
viruses [10]. Several interactions between viruses and the miRs in the host cells have been reported:
the virus may either avoid being targeted by the cellular miRs [11]; block the cellular miRs to regulate
key proteins in main signalling pathways [12,13]; synthesize their own viral miRs to create a more
favourable cellular environment to survive in the host cells [14], or simply use the cellular miRs to
their own advantage [15]. It should also be noted that host cell miR repertoires change dramatically in
response to various diseases. Several underlying cardiovascular and lung conditions may significantly
alter host miR expression, which would affect virus-host lung cell interactions, and may significantly
determine the course of the disease.
The existence of sequences within the ssRNA viral genome with a high degree of sequence
similarity to human (or mammalian) sequences is unlikely to be accidental. Hypothetically, some viral
ssRNA molecules may be channelled into the miR processing pathways influencing the host cell, whilst
other ssRNAs are packaged, combinations of which may increase overall viral activity. The general
prediction mechanism of putative miRs is based on the determination of seed region specificity.
The seed sequence, which is the critical part of the target prediction, is essential for the binding of the
miR to the target mRNA. The seed sequence or seed region is referred to as an evolutionary conserved
heptameric sequence, which is mostly situated at positions 2–7 from the miR 5’-end. Therefore, point
mutations at seed regions are critical to evaluate the target specificity and functional consequences of
the potential miR and target mRNA. The complex interaction between the viruses and the host miRs
mostly become more advantageous for the viruses as they enable them to avoid the immune system
response and allow them to employ the host’s miRs [16]. Recently it has been suggested that miRs
play a role in the host’s defence system against viral infections such as HIV-1, HSV, HCV, dengue and
influenza [17–21]. Therefore, targeting specific miRs could prove to be a novel strategy for treatment.
The best-known anti-miR treatment for viral infection is targeting miR-122 to cure HCV [18]. It has
also been reported that anti-miR-based HCV therapy is genotype independent, which makes it safe,
effective and well tolerated by patients [22].
In this study, our first aim was to identify human miRs that show sequence similarities to the
SARS-CoV-2 genome, and their conservation ratio in SARS-CoV-2 isolates obtained from different
geographical regions. Following determination of significantly similar miR sequences, we evaluated
their potential effect on host cells through analysis of their target genes and related KEGG and GO
pathways using bioinformatics tools. In the final part of the study, the miR-mediated alterations of
different pathways were compared to public transcriptome data obtained from SARS-CoV-2-infected
cell and tissue biopsy samples. To this end, the study aims to clarify the role of potential miR-mimic
sequences in the SARS-CoV-2 genome with their host target genes, which may propose a new
perspective for antiviral strategies.
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2. Material and Methods
2.1. Genome Sequences
The SARS-CoV-2 genome sequences from China, Italy, Spain (Valencia), and those for MERS,
SARS, OC43 and 229E were obtained from NCBI (GenBank: NC_045512.2, LC528232.1, MT066156.1,
MT198652.2, KT225476.2, NC_004718.3, NC_006213.1, NC_002645.1, respectively). The SARS-CoV-2
genome sequences from England (hCoV-19/England/20136087804/2020|EPI_ISL_420910, no treatment)
and Turkey (hCoV-19/Turkey/GLAB-CoV008/2020) were obtained from the China National Bioinformatics
Center, GISAID database [23] (https://www.gisaid.org). In addition, a SARS-CoV-2 strain isolated from a
Turkish patient, and infected to Vero E6 cells passage 4 sequence (hCoV-19/Turkey/ERAGEM-001/2020;)
was used for alignment studies with the miRBase mature miRNA search tool.
2.2. miR Prediction
The miRTarget and miRBase programmes were used to predict the similarities between the
SARS-CoV-2 genome and human miRs; e-value <10 and score >70 were considered as significant.
DianaTools miRPath V3 were then used to create heat maps for pathways affected by selected miRs,
focusing on the microT-CDS version 5.0 database. The p value threshold was 0.05 and microT threshold
was 0.8. Heatmap analysis was done with pathway intersection [24].
2.3. Mutational Analysis of Potential miRNA Sites
Viral genome sequencing data was obtained from the GISAID database (https://www.gisaid.org),
and analysed as multiple sequence alignments using the Clustal Omega at EBI (www.ebi.ac.uk/Tools/
msa/clustalo/).
2.4. Pathway Analysis
Bioproject data was obtained from PRJNA615032 bioproject trancriptome data, which includes
lung biopsies from SARS-CoV-2-infected patients and healthy volunteers as well as mock and
SARS-CoV-2-transfected NHEB and A549 cell lines. The data have been deposited with links to
BioProject accession number PRJNA615032 in the NCBI BioProject database (https://www.ncbi.nlm.
nih.gov/bioproject/). All the selected data were reanalysed at the Rosalind bioinformatics server.
Data analysis was performed according to 1.5 fold change between untransfected and transfected
cell lines in a data pool calculation for both cell lines at p < 0.05 significance level. Data was
analyzed by Rosalind (https://rosalind.onramp.bio/), with a HyperScale architecture developed by
OnRamp BioInformatics, Inc. (San Diego, CA, USA). Reads were trimmed using cutadapt [25].
Quality scores were assessed using FastQC [26]. Reads were aligned to the Homo sapiens genome
built by GRCh38 using STAR [27]. Individual sample reads were quantified using HTseq [28]
and normalized via relative log expression (RLE) using DESeq2 R library [29]. Read distribution
percentages, violin plots, identity heatmaps, and sample MDS plots were generated as part of the
QC step using RSeQC [30]. DEseq2 was also used to calculate fold changes and p-values and
perform optional covariate correction. Clustering of genes for the final heatmap of differentially
expressed genes was done using the PAM (partitioning around medoids) method using the fpc R
library (https://cran.r-project.org/web/packages/fpc/index.html). Hypergeometric distribution was
used to analyze the enrichment of pathways, gene ontology, domain structure, and other ontologies.
The topGO R library [31], was used to determine local similarities and dependencies between GO terms
in order to perform Elim pruning correction. Several database sources were referenced for enrichment
analysis, including Interpro [32], NCBI [33], MSigDB [34,35], REACTOME [36], and WikiPathways [37].
Enrichment was calculated relative to a set of background genes relevant for the experiment.
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3. Results
3.1. Analysis of SARS-CoV-2 Viral Genome for miR Sequences with High Human Similarity and
Functional Characterisation
The miRBase online database holds 2565 miR sequences and from these we identified regions of
the SARS-CoV-2 viral genome, which showed high similarity to human miRs. Similarly, we analysed
SARS-CoV-2 genomes obtained from different geographical areas for comparison. Despite the relatively
large SARS-COV-2 genome, only a few miRs were found to show similarities with human miRs (Table 1).
Table 1. Similar microRNA (miR) sequences found in SARS-CoV-2-released genomes from different
geographical areas.
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We have found five highly significant miRs from four different countries; Turkey, Italy, Spain,
and the UK; one RefSeq sequence from Wuhan and one SARS-CoV-2 genome from the VeroE6 cell
line: miR-8066 (e-values; 1.6 for Wuhan, 2.8 for Valencia, 1.6 for both Italy and England, 2.8 for
VeroE6 cells SARS-CoV-2 genomes); miR-5197-3p (e-values; 1.6 for Wuhan, 2.1 for VeroE6 cells, 2.8 for
Valencia and 1.9 for both Italy and England SARS-CoV-2 genomes), and miR-3611 (e-values; 2.8 for
Wuhan, 3.3 for Valencia and 2.8 for both Italy and England, 2.8 for VeroE6 cells SARS-CoV-2 genomes);
miR-3934-3p (e-values; 3.4–5.0), and miR-1307-3p (e-values; 4.3–6.3). We could, however, detect a
similar alignment with miR-1307-3p in SARS-CoV-2-infected Vero E6 cells. Additionally, we found
that the same miR sequences exist within four genomes of SARS-CoV-2, within the lower e-values
of 5.0–10.0 were miR-3691-3p and miR-1468-5p. Again, miR-3691-3p was not a positive hit in the
SARS-CoV-2-infected Vero E6 cell line. All of these miR similarities to human miRs were conserved in
all studied genomes. We then used DianaTools to identify the potential pathways to which these miRs
contribute (Figure 1). The functional characterizations of these highly conserved miRs were analyzed
with KEGG molecular pathways. The selected intersected pathways were analyzed as significant
targets as p value 0.05 with threshold value 0.8 and Fisher’s Exact Test (hypergeometric distribution)
calculations by miRPath version 3.0 in the microT-CDS database. As shown in Figure 1. miR-8066
and miR-5197-3p are critical on TGF-β and mucin type O-Glycan biosynthesis pathways. miR-8066 is
also related to cytokine-cytokine receptor interaction. miR-5197 is significantly related to morphine
addiction and metabolism of xenobiotics by cytochrome P450 mechanisms. These two miRs were highly
conserved, and their coexistence was significant within the four-genome search. miR-3611 was the other
leading miR, which possesses co-occurrence potential with miR-8066 and miR-5197 in all genomes
that were effective on GABAergic synapse, morphine addiction and metabolism of xenobiotics by
cytochrome P450 mechanisms. Although co-occurrences of miR-1468-5p and miR-1307-3p were similar
to miR-3611, it was less effective on all evaluated metabolic pathways. miR-3934-3p was effective on
glycosaminoglycan biosynthesis—heparan sulfate/heparin, other types of O-glycan biosynthesis, and
vitamin digestion-absorption mechanisms, respectively.
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Figure 1. Heat map analysis of KEGG pathway (A) and GO analysis (B) for selected miRs on the
microT-CDS database. The heat map is drawn with miRPATH (version 3). Neighbourhood lines
indicate the shared target mRNAs found in a defined pathway.
Viruses 2020, 12, 614 10 of 27
When we evaluated significant union gene-based pathway alterations for selected miRNAs,
we found that mucin type O-glycan biosynthesis, morphine addiction, TGF-β signaling pathway,
axon guidance and GABAergic synapse mechanisms were significantly affected according to KEGG
pathway analysis on the miRPath (Table 2A).
Table 2. The KEGG (A) and GO (B) enrichment analysis results for miR-8066, 5197-3p, 3611, 3934-3p,
1468-5p, 3691, and 1307-3p.
KEGG Pathway (A) p-Value #genes #miRNAs
Mucin type O-Glycan biosynthesis 2.52 × 10−2 7 3
TGF-beta signaling pathway 4.96 × 10−1 12 4
Morphine addiction 0.0001128919 14 5
Metabolism of xenobiotics by cytochrome P450 0.0002215491 5 2
Other types of O-glycan biosynthesis 0.0003646344 1 1
Vitamin digestion and absorption 0.001008222 2 1
Glycosaminoglycan biosynthesis—heparan sulfate / heparin 0.00385809 1 1
GABAergic synapse 0.01342039 13 4
Cytokine-cytokine receptor interaction 0.02096334 9 1
Signaling pathways regulating pluripotency of stem cells 0.180299 9 1
Amphetamine addiction 0.2150865 7 1
Axon guidance 0.2239648 22 3
Hippo signaling pathway 0.2278356 7 1
Prolactin signaling pathway 0.2284669 5 1
mRNA surveillance pathway 0.2795597 1 1
Glycosphingolipid biosynthesis—lacto and neolacto series 0.3157068 1 1
Bile secretion 0.4120997 1 1
Circadian entrainment 0.4608082 9 1
N-Glycan biosynthesis 0.488078 2 1
Mismatch repair 0.6174557 1 1
Drug metabolism—cytochrome P450 0.7063987 6 1
Glutamatergic synapse 0.7319762 6 1
Glycosaminoglycan degradation 0.7395672 2 1
Antigen processing and presentation 0.7591685 1 1
GO Category (B) p-Value #genes #miRNAs
organelle 1 × 10−38 848 6
cellular nitrogen compound metabolic process 1 × 10−12 414 7
ion binding 8 × 10−8 495 7
biosynthetic process 3 × 10−7 351 7
nucleic acid binding transcription factor activity 4 × 10−2 115 6
cellular protein modification process 2 × 101 205 7
molecular_function 5 × 103 1303 7
cellular_component 1 × 105 1312 7
enzyme binding 2 × 105 119 5
gene expression 3 × 105 54 6
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Table 2. Cont.
GO Category (B) p-Value #genes #miRNAs
protein binding transcription factor activity 1 × 106 52 5
blood coagulation 0.000176061599974 44 6
protein complex 0.00115693944276 290 5
post-translational protein modification 0.00185490003064 19 5
neurotrophin TRK receptor signaling pathway 0.00197464302174 24 5
synaptic transmission 0.00204631087649 42 5
cellular protein metabolic process 0.00275618650845 39 5
small molecule metabolic process 0.00275618650845 170 7
cytoskeletal protein binding 0.00396272124679 68 4
cell-cell signaling 0.00396272124679 60 5
transcription, DNA-templated 0.00450420995446 208 6
symbiosis, encompassing mutualism through parasitism 0.0140041886634 41 5
catabolic process 0.0141620388146 142 6
Fc-epsilon receptor signaling pathway 0.0222360628043 15 6
cellular component assembly 0.02375306792 99 5
transcription initiation from RNA polymerase II promoter 0.0250016205995 24 5
nucleoplasm 0.0335128910566 92 6
platelet activation 0.0350801245107 20 5
positive regulation of telomere maintenance via telomerase 0.0370638891992 3 3
RNA polymerase II core promoter proximal region
sequence-specific DNA binding transcription factor activity
involved in positive regulation of transcription
0.0448871926331 32 5
O-glycan processing 0.0449415771561 8 5
In a similar setting, GO enrichment analysis results were again obtained from miRPath analysis.
We determined that the clusters, based on the selected miRs’ target genes, were organelle, cellular
nitrogen compound metabolic process, ion binding, biosynthetic process, nucleic acid binding
transcriptional factor activity, and cellular protein modification process (Table 2B).
In the current analysis, we detected mutations in miR-1307 and miR-8066 only. Additionally,
a mutation on miR-129-2-3p was found on only the Icelandic SARS-CoV-2 genome (Table 3). Moreover,
miR-129-2-3p is one of the selected miR (Table 1) found only in the Wuhan and Italy genomes, although
in less than 5% of the genomes sequenced. These three miRs are potentially involved in mucin type
O-glycan biosynthesis, TGF-β signalling pathway, amphetamine addiction, cytokine-cytokine receptor
interaction and nicotinate-nicotinamide metabolism. All of these pathways are associated with host
responses against SARS-CoV-2, and virus pathogenesis in host cells. The mutations on selected miRs
may affect their presence in different strains and may alter their potential host-mediated responses.
The remainder of the miRs, presented in Table 3, was found to be conserved. Therefore, our data suggest
that either these sequences are crucial for SARS-CoV-2, or their locations are important for the virus to
survive. Using the GISAID database, we analysed a sample of viral genomic sequences from several
geographical areas for mutations in the potential miR sequences (n = 28–133). The majority of the miRs
studied showed very few base changes in these sequences, with <1% overall. MiRs miR-1468-5p and,
particularly, miR-1307-3p showed an increased percentage of mutations. All the mutations analysed
reduced the microRNA base similarity and decreased the score value to below significance (<70).
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Table 3. The mutational comparison of selected miRs found on the Wuhan genome compared to
other SARS-CoV-2 strains isolated from different geographical regions. % represents the number
of viral genome sequences with a single base change in that miR sequence. n = number of viral
genomes analysed.
miRs Alignment
Wuhan/
China Italy Spain France England USA India
n = 28 n = 44 n = 133 n = 104 n = 104 n = 104 n = 34
hsa-miR-8066 ccaaaagaucacauug 0 0 0 0 0 0 0
hsa-miR-5197-3p auucgaagacccagucccuacuu 0 0 0 0 0 0.9% 0
hsa-miR-3611 ugagaagcaagaaauucuu 0 0 0 0 0 0 0
hsa-miR-3934-3p ucagguuggacagcugg 0 0 0 0 0 0 0
hsa-miR-1307-3p accgaggccacgcggagu 3.5% 2.2% 8.27% 1.92% 2.88% 2.88% 38.23%
hsa-miR-3691-3p gagauguugacacagacuuugu 0 0 0 0 0 0 0
hsa-miR-1468-5p cucaguuugccuguuu 0 0 2.25% 0.96% 0 0 8.83%
hsa-miR-3120-5p uguagaggaggcaaagacag 0 0 0 0 0 0 0
hsa-miR-3914 caucucacuugcugguuccu 0 0 0 0 0 0 0
hsa-miR-3672 ugagucucauggaaaaca 0 0 0.75% 0.96% 0 0 0
hsa-miR-378c acugggcauugauuuagaugagugg 0 0 0 0 0 0 0
hsa-miR-7107-3p ccaaaaagagaaagucaaca 0 0 0 0 0 0 0
hsa-miR-1287-5p acucaaaccacugaaacagc 0 0 0 0 0 0 0
hsa-miR-10397-5p uucuucaccugaugcugu 0 0 0 0 0 0 0
hsa-miR-584-3p gccugguuugccuggcac 0 0 0.75% 0 0 0 0
hsa-miR-3085-3p ucuggcuguuauggcc 0 0 0 0 0 0.96% 0
hsa-miR-3191-3p cugucuauccaguugcgucacca 0 0 0 0 0 0 0
hsa-miR-3529-3p uggcagacgggcgauuuuguu 0 0 0 0 0 0 2.94%
hsa-miR-3682-5p auagcacaaguagauguag 0 0 0 0 0 0.96% 0
hsa-miR-148b-3p aaguucuaugaugcacag 0 0 0 0 0 0 0
hsa-miR-129-2-3p ugauuuuuguggaaagggcu 0 0 0 0 0 0 0
Due to the increased mutation ratios in SARS-CoV-2 strains isolated from different geographical
regions, we checked the conservation of miR mimic sequences in different sequence results.
The comparison of depicted miR sequences from different SARS-Cov-2 strains (Table S1), with
the Wuhan SARS-CoV-2 (HCOV-19/WUHAN/WH01/2019|EPI_ISL_406798|2019-12-26), was analyzed
by BLAST nucleotide search with default values.
3.2. Analysis of Gene Alterations in NHEB Bronchial Epithelial and A549 Cells Due to SARS-CoV-2 Infection
In the final part of the study, we analyzed the gene expression alterations due to SARS-
CoV-2-mediated infection in NHEB bronchial epithelial cells and A549 lung cancer cell lines. For this
purpose, we used the Bioproject PRJNA615032 publicly available data with the Rosalind bioinformatics
data analysis server.
The meta-analysis results were evaluated for the differential gene expression at a 1.5 fold
change cut-off level. In total, 124 genes were selected according to a statistical p value threshold
of <0.05, and analyzed for the related signaling axis to understand the disease pathophysiology,
as shown in Figure 2A,B. While 104 genes were upregulated in SARS-CoV-2-infected cells, 20 genes
were downregulated.
All of these genes were also analysed using cluster analysis tools provided by the Rosalind
bioinformatic data analysis server for different pathways. As shown in Table 4, the Wiki pathways,
Bioplanet, KEGG, REACTOME, Panther, Pathway Interaction DB, and the number of virus-host response
pathways, were significantly altered. These significantly altered pathways showed correspondingly
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similar patterns with SARS-CoV-2-mediated known clinical pathologies. These pathways were based
on major differences of the target genes for inflammation responses.
Figure 2. Rosalind meta-analysis for Bioproject PRJNA615032 was used for differential gene expression
between SARS-CoV-2-infected NHEB and A549 cells with their (mock treated) controls (n = 3). 1.5 fold
change was accepted as threshold value. (A) MA plot view of differential expression of upregulated and
downregulated genes. (B) Heatmap analysis of each clone for 204 differentially expressed gene targets.
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Table 4. BioProject data analysis for differential gene expression between non-treated and SARS-
CoV-2-treated NEHB and A549 cells.
WikiPathways p-Adj
Photodynamic therapy-induced NF-kB survival signaling 0
IL-18 signaling pathway 8.6 × 10−9
miRNAs involvement in the immune response in sepsis 2.4 × 10−8
Cytokines and Inflammatory Response 9.9 × 10−7
Lung fibrosis 2.5 × 10−6
BioPlanet p-Adj
Oncostatin M 0
Interleukin-1 regulation of extracellular matrix 0
Interleukin-5 regulation of apoptosis 0
TNF-alpha effects on cytokine activity, cell motility, and apoptosis 0
Immune system signaling by interferons, interleukins, prolactin, and growth hormones 0
KEGG p-Adj
IL-17 signaling pathway 1.3 × 10−9
TNF signaling pathway 1.6 × 10−9
Legionellosis 3.5 × 10−9
Rheumatoid arthritis 5.4 × 10−9
Cytokine-cytokine receptor interaction 6.6 × 10−9
PANTHER p-Adj
Plasminogen activating cascade 0.00156
Toll receptor signaling pathway 0.00911
CCKR signaling map ST 0.02550
Apoptosis signaling pathway 0.10282
Blood coagulation 0.10433
REACTOME p-Adj
Interferon alpha/beta signaling 1.6 × 10−9
Interleukin-10 signaling 2.5 × 10−9
Interleukin-4 and Interleukin-13 signaling 2.4 × 10−7
Formation of the cornified envelope 1.3 × 10−5
Chemokine receptors bind chemokines 0.00047
Small Molecule Pathway DB p-Adj
CD40L Signalling Pathway 0.25268
NF-kB Signaling Pathway 0.25268
Toll-Like Receptor Pathway 2 0.25268
Capecitabine Metabolism Pathway 0.25268
Capecitabine Action Pathway 0.25268
BIOCYC p-Adj
vitamin D3 biosynthesis 0.03597
guanosine nucleotides degradation 0.03597
retinoate biosynthesis II 0.03597
guanosine nucleotides degradation III 0.03597
adenosine nucleotides degradation II 0.03597
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Table 4. Cont.
Pathway Interaction DB p-Adj
Validated transcriptional targets of AP1 family members Fra1 and Fra2 3.8 × 10−5
IL23-mediated signaling events 0.00050
CD40/CD40L signaling 0.02539
Glucocorticoid receptor regulatory network 0.02603
LPA receptor mediated events 0.04171
The predicted pathways in cell lines showed similar significance with selected miRs that mainly
target inflammation and virus pathogenesis (Figure 1 and Table 2). Thus, we concluded that the
selected miRs, that showed high similarity with human miRs, are also the critical targets, which project
the major clinical pathophysiological conditions related to pathway alterations.
4. Discussion
In the current study, we identified potentially similar miR sequences of human miRs and
SARS-Cov-2 strains from different geographical regions. For this purpose, we selected different
genome sequence studies released recently in PubMed®and GISAID databases, which included
genome results for SARS-CoV-2 strains from four different geographical regions. We first aligned all
the sequences with the mature hsa-miR database presented in miRBase. During this study, we made
a cluster according to the co-existence of significantly aligned hsa-miRs with the SARS-CoV-2 genome
and their biological significance in human cells. miRPath version 3 was used for the determination of
the selected miRs’ potential biological effects via searching target gene-related results found in the
KEGG and GO pathways. The mutational alterations were also analyzed for different miRs, which
showed significant alignment scores with SARS-CoV-2 genomes from other geographical regions.
Concomitantly, we also analyzed and compared Bioproject PRJNA615032 trancriptome data obtained
from normal vs SARS-CoV-2-infected lung tissue biopsy samples. Data was submitted by tenOever Lab,
Microbiology, Icahn School of Medicine at Mount Sinai on 24-Mar-2020. In addition, the gene expression
differences between A549 and NHEB cell line data and the gene expression differences between normal
and infected lung tissue samples were analyzed in the REACTOME database (https://reactome.org/)
to propose the potentially affected signaling axis members. The clinical outcome of severe condition
patients is discussed below, for selected miRs and their potential biological importance in host cells.
4.1. Biological Significance of Top Ranked miRs in Humans
4.1.1. miR-8066
Recently, the N nucleocapsid gene-related putative miR candidates were shown through in silico
prediction tools [38]. In a similar manner, we determined miR-8066, a mature sequence found on
SARS-CoV-2 genomes, in SARS-CoV-2 genome alignment analysis with human miRs. Additionally,
miR-8067, which possesses a similar biological role to miR-8066, was identified as a stem loop region
sequence in all SARS-CoV-2 genomes (Figure S1). Previous reports showed that both miRs are found
in plasma samples of sepsis patients with severe clinical outcomes [39]. Similar miR family members
such as miR-8054, miR-8057, miR-8061, and miR-8068, were also found in a non-survivor group of
sepsis patients. It has been shown by in silico analysis that certain miRNAs have the core motifs of
AUUGUUG, and that miR-8066 is one of these [40]. When miRs have this motif, it increases their
likelihood to bind and activate Nf κB-mediated TLR-8 expression and induce cytokine synthesis [40].
miR-8066 was identified at high levels in tissue biopsies as well as in exosomes [41]. Therefore,
SARS-CoV-2-mediated alterations of miRs may act as autocrine or paracrine agonists of host cells
to trigger pro-inflammatory cytokines, due to their increased NfKB activity [42]. Similar findings
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were also suggested for cancer cells, which showed miR alterations in association with inflammation
markers [43].
There is preliminary data about the existence of sequence similarity of human miRs in the
spike region of the SARS-CoV-2 genome for both forward and reverse complementary strands [44].
Hsa-miR-8055, which was also previously shown to be a sepsis marker, was found to be involved
in T-cell responses to specific antigens [45]. One of the differentially expressed circRNAs in children
with fulminant myocarditis, Circ_0071542, was suggested to regulate the expression of MAPK,
a well-characterized target in the development of disease through binding hsa-miR-8055 [45]. In our
current study, we found that the miR-8066 sequence is present in four different SARS-CoV-2 genomes and
shows strong association in KEGG pathways for TGF-beta signalling, mucin type O-glycan biosynthesis
and cytokine-cytokine receptor interaction. These targeted pathways are known, critical mediators for
the clinical outcomes for SARS-CoV-2-infected patients and give us insight about virus pathophysiology.
It is well established that for enveloped viruses, such as SARS-CoV-2, N- or O-glycosylation of S
protein determines the viral entry and membrane fusion with functional elicitation of host immune
responses [46]. The high-resolution LC-MS/MS experiment was performed to detect site-specific
quantitative N-linked and O-linked glycan profiling on SARS-CoV-2 subunit S1 and S2 proteins.
The glycan profiling showed that two unexpected O-glycosylation sites on the receptor-binding domain
(RBD) of subunit S1 increased the pathogenicity of SARS-CoV-2. Therefore, our understanding of
complex sialylated N-glycans and sialylated mucin type O-glycans on the functional RBD domain may
help to evaluate better therapeutic or vaccine strategies [47]. Moreover, miR-8066 alters N-glycosylation
patterns according to the microT-CDS pathway and may have biomarker potential for this mechanism.
In addition, miR-8066 is found to be associated with one of the critical clinical problems of COVID-19,
the cytokine storm, owing to its potential effect on the cytokine-cytokine receptor pathway. It is
well established that miR-8066 affects PRLR, CXCL6, IL6, IL17 and ACVR1 target genes, which
are crucial members of the cytokine regulatory network (Table 2). According to previous NGS
platform results obtained from healthy versus SARS-CoV-2-infected lung tissue biopsies (Bioproject
PRJNA615032), the most highly upregulated pathways are chemokine binding receptors (p value
7.94 × 10−4), FGFR activation pathways (p value 0.002) and its downstream pathway (p value 0.001),
neutrophil degranulation (p value 0.003), and IL10 (p value 0.005), when compared with normal lung
tissue biopsies (Table S2). On the contrary, according to the REACTOME pathway analysis of Bioproject
PRJNA615032 data, neutrophil degradation was also downregulated in SARS-CoV-2-infected biopsy
specimens (p value 1.74 × 10−6). Briefly, the downregulation of host cell responses’ related pathway
members such as SRP-dependent co-translational protein targeting to membrane, L13a-mediated
translational silencing of ceruloplasmin expression antigen processing, ribosomal organization, and the
ERAD pathway, were observed in COVID-19-positive lung biopsy specimens. All of these preliminary
gene expression differences, between normal and SARS-CoV-2-infected lung biopsies, are associated
with detected miR pathways and highlight common clinical presentations of patients. Each of these
biological mechanisms, according to potential disease progression-related alterations in the host
genome, is highly associated with TGF-β, which is a cytokine affecting a number of host responses
during infection [48]. TGF-β mediates the immune responses of host cells, as well as altering tissue
remodelling by affecting cell survival, apoptosis and migration. It has been demonstrated that
SARS-CoV N protein potentiate Smad-3 mediated TGF-β activation, and plasminogen activator
inhibitor-1 (PAI-1), leading to severe pulmonary fibrosis and inactivation of pro-apoptotic genes by
complex formation of Smad3 and Smad4 [48].
4.1.2. miR-5197
miR-5197-3p was identified as the most effective miR to interact with the guide RNA of SARS-CoV,
MERS-CoV and COVID-19 [49]. According to a recent study, out of 2565 miRNAs, only three critical
miRs, 5197-3p, 4778-3p and 6864-5p could interact with complete complementary miR (cc-miR) and
possess a critical therapeutic potential due to their binding affinity on SARS-CoV-2 guide RNA. It was
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suggested that the generation of miR-5197-3p-based complete complementary miRNA may possess a
significant therapeutic response, owing to its structural affinity to guide RNA of SARS-CoV-2, without
any side effects on human genes [49]. Previous patents on hsa-miR-5197-5p indicated that any drug
targeting this miR might be critical in the treatment of hepatitis B infections (WO2018193902A1).
Similar to this finding, it was shown that miR-5197-3p might be used in vaccine strategies in the herpes
simplex virus (HSV-1) (WO2013109604A1WO2013109604A1).
In another study, allelic variances of hsa-miR-5197 were found to be highly associated with
non-small cell lung cancer (NSCLC) [50]. According to the Harvard and MD Anderson databases,
miR-5197 shows significant differences between Caucasians and Chinese populations (data gained
from a Han Chinese cohort from Nanjing, China) [50]. The rs2042253 polymorphism (T>C variation)
of miR-5197 provided a protective effect on lung cancer survival. Moreover, this SNP is reported to
have a high read frequency for paediatric acute lymphoblastic leukemia (ALL) in the UK cohort [51].
High throughput analysis of 408 lung cancer patients showed that miR-5197 polymorphism is highly
correlated with chemotherapy-induced severe toxicity [52]. It has been accepted that nucleotide
variations in pre-miRNAs may have contributed to the stability of stem-loop structure and may affect
recognition sites for Drosha and Dicer cleavage [53]. In our current study, we did not find any mutations
in miR-5197 sequences obtained from different SARS-CoV-2 genomes, however we found that mucin
type O-glycan biosynthesis was related to both miRs 5197-3 and 8066. This KEGG pathway has been
involved in the cell-to-cell transmission of human T cell leukemia virus type 1 (HTLV-1) [54] and plays
roles in Ebola virus cell attachment [55]. HIV-1 infection of T cells has also been shown to result in
altered glycosylation of cell surface glycoproteins [56].
O-glycans are also linked to avian influenza [57]. Mucosal O-linked glycans are furthermore
associated with herpes simplex virus 1 infection [58]. Mucin type O-glycan biosynthesis miR pathways
have been identified in avian oncogenic retrovirus (Avian leukosis virus subgroup J (ALV-J)) [59].
This KEGG pathway is therefore related both to human as well as veterinary viral infections and
further studies will be needed to establish the function of miR-5197 during SARS-CoV-2 infection.
4.1.3. miR-3611
In our current study, we found that miR-3611 is a positive hit for stem loop region and mature
miRNA prediction. Because of its potential presence in SARS-CoV-2-mediated cellular responses,
we have analysed data from the lung tissue biopsy database (PRJNA615032 Bioproject) to understand
its function. A previous study reported altered miRNA expression in chronic obstructive pulmonary
disease (COPD). COPD is an airway disorder and respiratory disease that is associated with persistent
inflammation [60]. A study on miR expression analysis, conducted on COPD and healthy volunteers,
showed significant down-regulation of miR-3611 expression in COPD patients [61]. The long non-coding
RNA, H19, has been linked to many carcinomas, including lung cancer [62]. It has been shown that
miR-3611 is significantly down-regulated in a H19 knockdown lung cancer cell line (SPC-A1), which
indicated overexpression of this miR in ‘normal’ H19 intact lung cancer cell lines [63]. In our study,
we identified that miR-3611 shows high similarity with all four main SARS-CoV-2 genomes and
we did not detect any mutations between genomes. However, miR-3611 was strongly associated
with KEGG pathways for metabolism of xenobiotics by cytochrome P450, morphine addiction and
GABAergic synapse. Moreover, morphine addiction was, besides linkage with miR-3611, also linked
to miR-5197-3. This KEGG pathway has been related to enhanced HIV-1 infection [30] and morphine
treatment has been shown to promote HIV-1 replication in macrophages via inhibition of the TLR9
pathway [64]. Furthermore, an increased rate of HIV-1/HTLV-I infection has been observed due to
morphine in injection drug users [65]. Morphine is also associated with enhanced hepatitis C virus
(HCV) replicon expression [66,67]. Opioids have furthermore been shown to enhance simian acquired
immunodeficiency syndrome (SAIDS) in rhesus monkeys [68], while reduced clearance of pulmonary
influenza virus infection was observed in morphine-treated Lewis rats [69]. Interestingly, opioids such
as morphine are also used as indirect antitussives to suppress cough, which is commonly associated
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with respiratory viral infections [70], including SARS-CoV-2. Indeed, morphine was used in recent
cases in China during sedation and analgesia for endotracheal intubation, to avoid patients’ cough and
agitation during the procedure [39]. In light of the association of morphine with promotion of viral
replication, it may have effects in SARS-CoV-2 that need to be further investigated.
4.1.4. miR-3934-3p
miRNA expression profiles have been used to classify cancers into various subtypes. miR3934 is
found upregulated in colon cancer and was suggested as a biomarker for lung cancer as its expression
correlated with survival rate and prognosis of NSCLC [71,72]. Moreover, it has been reported that
miR-3934-5p expression significantly increases in NSCLC cell line A549 [73]. It is also a SNP linked to
TGF-β signalling and has been identified as downregulated in rectal carcinoma mucosa, compared
with normal mucosa [74].
In addition, it was shown that miR-3934-3p downregulated TGFBR1 and SMAD3. In a similar
vein, HSV-1 viral infection led to a significant down-regulation of these targets [74]. Moreover,
the activation of the TGF-β/Smad pathway is critical for lung fibrosis, which was previously shown in
SARS-CoV-related cases. Dysregulation of ACE2 may influence the toll-receptor signalling pathway,
via IL6, and affect downstream immune responses. Irrespective of SARS-CoV-2 or pneumonia in
TCGA-LUAD, the altered immunoreaction was the primary cause (lung adenocarcinoma; SARS-CoV-2;
ACE2; miR-125b-5p; IL6). TGF-β and cigarette smoke have been shown to suppress miR-141-5p to
promote CCR5 expression on primary bronchial epithelial cells, which results in increased viral entry
and infection by R5-tropic HIV [75]. Given that TGF-β signalling is upregulated by trans-activator (Tat)
protein, cigarette smoke and in chronic lung diseases, it has been determined the effects of persistent
TGF-β signalling on HIV infection in primary bronchial epithelium re-differentiated ex vivo [75]. In our
current study, miR-3934-3p was found to be associated with KEGG pathways for glycosaminoglycan
biosynthesis heparan sulfate/heparin, mucin type O-glycan biosynthesis and vitamin digestion and
absorption. The relevance of these pathways is as follows:
“Glycosaminoglycan biosynthesis—heparan sulfate/heparin” was here related to miRs 3934-3.
Heparan sulfate proteoglycans have previously been identified to provide the binding sites for
SARS-CoV-2 invasion at the early attachment phase [76]. Furthermore, human coronavirus NL63
has been shown to utilise heparan sulfate proteoglycans for target cell attachment [77]. This KEGG
pathway has been related to Ebola virus, where heparan sulfate has been identified as an important
mediator in polarised epithelial cells [78,79]. In hepatitis C viral infection, the virus hijacks this
pathway via interaction with apolipoprotein E for cell entry [63], while heparan sulfate proteoglycans
are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection [70].
Endogenous HERV-K furthermore binds to heparin for cell entry [80], and, while heparin has been
found to further Zika virus infection, it acts as an antiviral against Dengue replication [81]. Heparin
sulphate is identified as an inhibitory regulator of porcine epidemic diarrhoea virus infection [82] and
acts as an attachment factor for rabies virus entry and infection [83], as well as an enhancer of Nipah and
Hendra virus infections, which are highly pathogenic, zoonotic paramyxoviruses [84]. This highlights
the importance of this KEGG pathway both in human, zoonotic and veterinary viral infections.
Another important pathway, vitamin digestion and absorption, was found to be related to
miR-3934-3. This KEGG pathway has been highlighted amongst others as a link between dysbiosis of
the gut microbiome and chronic diseases [85]. Furthermore, intestinal triglyceride-rich lipoproteins
have been related to vitamin metabolism in relation to coronary artery disease as well as viral
infections [86]. In AIDS, malabsorption of vitamin 12 has been related to gastric secretory failure,
including chronic diarrhoea, due to advanced HIV infection [87,88]. Additionally, vitamin A deficiency
has been associated with more progressive HIV disease [89]. Veterinary viral infections, such as
infectious bronchitis virus (IBV) and reovirus (RV) in chickens, have been identified to affect vitamin
A metabolism due to epithelial damage [90]. Interestingly, a link between vitamin D deficiency and
SARS-CoV-2 infection severity was recently reported [91]. Also, vitamin B3 was found to be highly
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effective to help lung tissue damage repair [92] and it was suggested to be given to COVID-19 patients
as soon as the CT lung abnormalities were detected [93].
4.1.5. miR-1307-3p
miR-1307 has previously been shown to be one of the lung-tissue-associated miRs [94] and
was reported as an especially important target in lung development in newborns. Expression of
mir-1307-3p has furthermore been linked to acid metabolism in response to aspirin in human cardiac
and peri-cardiac fat-derived mesenchymal stem cells (MSCs) [95]. Moreover, it was shown that
several miRs, including miR-1307-3p, are involved in TGF-β and semaphorin signalling, as well as
inflammatory responses. miRs play an important role, especially during lung morphogenesis in
the early stages of development. Interestingly, miR-1307 has been associated with the severity of
pulmonary hypertension in systemic scleroderma [96]. Persistent problems with SARS-CoV-2-infected
patients, such as oxygen dependency, urgent need for mechanical ventilation, persistent wheezing,
and increased risk for pulmonary infections correlate with involvement of miR-1307-3p, as indicated
above, due to its role in pulmonary hypertension and chronic lung diseases. The TGF-β superfamily
plays critical roles in pre- and postnatal lung development, importantly shaping alveolarisation and
controlling the extracellular matrix composition and tissue homeostasis, among other functions. TGF-β
signalling is therefore strongly linked to both pulmonary and cardiovascular diseases [97–99].
4.1.6. miR-3691-3p
It has been shown that oxidative stress, which has detrimental effects on intercellular
communication, plays an important role in many lung pathologies such as acute lung injury and COPD.
A proteomic profile of exosomes from human bronchial epithelial cells, under normoxia and hypoxia,
has reported reduced expression of miR-3691-3p in hypoxia [100]. Interestingly, miR3691-3p targets
several cell signalling pathways, such as TGF-β signalling, FGF2 and also VCAM1, which is relevant
for lung injury and repair. In the current study, we have also identified that miR3691-3p exists in four
of the genomes, which we have extensively studied here, and therefore it seems to be a conserved miR.
4.1.7. miR1468-5p
Sudden cardiac death is a major problem amongst the unexplained deaths in COVID-19, and it has
been identified that many of those patients suffered from primary myocardial fibrosis (PMF), without
any known aetiology. Recently, higher expression of miR-1468-3p was identified as a disease-associated
and age-dependent cardiac biomarker, as it promotes cardiac fibrosis and cell senescence, although
no difference was noted in the mature form of miR-1468 between healthy and COVID-19-diseased
cardiac tissue [101]. TGF-β1 plays a key role in fibrosis-related pathologies including cardiac fibrosis,
and, furthermore, miR-1468 activates non-canonical TGF-β1 and MAPKs signalling pathways [101].
Moreover, miR-1468-5p expression has been found to be upregulated in regulatory T cells, which have
a significant role in autoimmune disorders, transplant rejection, allergic diseases, and asthma [102].
miR-1468-5p has previously been associated with glioma, where it inhibits growth and cell cycle
progression by targeting ribonucleotide reductase large subunit M1 (RRM1), based on a study on
patients from the Chinese Glioma Genome Atlas [103]. miR-1468-5 is also linked to progressing
hepatocellular carcinoma [104]. Interestingly, in Alzheimer’s disease, miR-1468-5p has been identified
to be at lower abundance compared with healthy controls [105]. It has furthermore been identified
as a biomarker in late seizure in patients with spontaneous intracerebral haemorrhage [49]. The link
between miR-1468-5 in viral infection and other comorbidities will need to be further investigated.
miR-129-2-3p, here identified as a common mutated miR, has previously been identified
as a regulator in human cancer development and progression [106]. It has been identified as
a diagnostic and prognostic biomarker for renal cell carcinoma [107] and a suppressor of serous
ovarian cancer [104]. Its upregulation suppresses breast cancer cell proliferation and induces its
apoptosis, while downregulation, via hypermethylation, increases breast cancer progression due to
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BCL2L2 overexpression [107]. It furthermore attenuates cell migration and invasion in renal cell
carcinoma by affecting the downregulation of various metastasis-related genes [108]. miR129-2 has
been linked to a range of haematological malignancies, including lymphoma [109]. It is also linked
to lung adenocarcinoma including regulation of cell proliferation [110], as well as to hepatocellular
carcinoma [111]. Interestingly, miR-129-2-3p has been found to be upregulated in human papilloma
virus-positive (HPV) head and neck squamous cell carcinoma [112] and in HPV transfected keratinocyte
cells [113]. In the light of increasing understanding of the link between SARS-CoV-2 and comorbidities,
underlying changes in miR-129-2-3p expression may be of considerable importance.
A number of KEGG pathways have been strongly linked to the main miRs identified as being related
to sequences within the SARS-CoV-2 genomes. These include: “Mucin type O-glycan biosynthesis”,
“TGF-β signalling pathway”, “Morphine addiction”, “Metabolism of xenobiotics by cytochrome P450”,
“Other types of O-glycan biosynthesis”, “Vitamin digestion and absorption”, “Glycosaminoglycan
biosynthesis—heparan sulfate/heparin”, “GABAergic synapse”, “Cytokine-cytokine receptor interaction”,
“Signalling pathways regulating pluripotency of stem cells”, “Amphetamine addiction”, “Axon
guidance”, “Hippo signalling pathway”, “Prolactin signalling pathway”, “mRNA surveillance pathway”,
“Glycosphingolipid biosynthesis—lacto and neolacto series”, “Bile secretion”, “Circadian entrainment”,
“N-glycan biosynthesis”, “Mismatch repair”, “Drug metabolism—cytochrome P450”, “Glutamatergic
synapse”, “Glycosaminoglycan degradation”, “Antigen processing and presentation”. The relevance of
several of these KEGG pathways has been discussed above in direct relation to the various miRs and
provides a novel insight into the putative interplay of these pathways and the microRNAs identified
in COVID-19, and may also help in furthering understanding of the interplay of miRs, viral infections
and comorbidities.
5. Conclusions
Previous epidemics have been caused by betacoronaviruses, especially in Asia. As expected, several
similarities and differences in the epidemiology, clinical features, and management of SARS, MERS, and
SARS-CoV-19 were seen [114]. However, none of the previous infections has caused global pandemics
of the scale currently caused by SARS-CoV-2. In our study, analysis of several SARS-CoV-19 genomes,
which were isolated from different geographical regions, shows significant similarity scores with
human miRs, which target a subset of genes related to pathways affecting virus pathogenicity and host
responses observed in COVID-19 patients. The numbers of in silico prediction-based studies that show
miRNA mimicking sequences of SARS-CoV-2 genome and miR-mediated host responses are increasing.
It was suggested that, as hsa-miR-4661-3p may target the S gene of SARS-CoV-2, and a virus-encoded
miRNA miR147-3p could enhance the expression of TMPRSS2 to promote SARS-CoV-2 infection in
the gut, host miRs are critical in the progression of the disease. In our current study we identified
that seven completely complementary miRNAs of COVID-19 (cc-miRc) prevent viral replication and
protein translation processes. Similar predictions and biological proofs were determined for MERS
and SARS-CoV [115,116].
By way of comparison to other human coronaviruses, multiple sequence alignment was carried out,
comparing the four SARS-CoV-2 sequences with those from SARS, MERS and two cold viruses, OC43
and 229E (Table S3), [115]. The symptom spectrum for these viruses differ from that of SARS-CoV-2,
therefore it is instructive to see if the miR-like sequences are present. We identified seven key miRs,
which highlight considerable differences between the SARS-CoV-2 sequences, compared with the other
viruses (Table S2). In each case, the four SARS-CoV-2 sequences are identical, but, for the most part,
the level of conservation in the other genomes is poor. Across the four sequences, which for SARS
generally show the highest degree of conservation: one ‘miR’ is completely conserved (miR-1468),
while others range from two to ten nucleotide differences. Whilst it is possible that this decrease
in similarity could result in reduced levels of transcriptional control, it is clear that there will be
a change in the physiological effect of the virus. The proposed miR1307 has been suggested as a
therapeutic target in the prevention of SARS-CoV-2 infection. Therefore, more studies on in silico
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patterns within the SARS-CoV-2 genome may provide a deeper understanding about miR-based novel
therapeutics [117,118]. MERS shows greater divergence across these segments and the two milder
symptom viruses show even greater differences or even significant sequence gaps. This divergence
away from the SARS-CoV-2 sequences broadly mirrors the phylogenetic relationships obtained from
the whole-genome alignments. Thus it can be argued that patterns of mutation, occurring during
sequence divergence from the longer established human viruses to the more recent ones, have led to
the emergence of sequence motifs that can be related directly to the pathogenicity of SARS-CoV-2.
This mechanism could have considerable significance in determining the symptom spectrum
of future potential pandemics. KEGG pathway analysis revealed a number of critical pathways
linked to the seven identified miRs that may provide insight into the interplay between the virus
and comorbidities.
Based on our reported findings, miRs may constitute a potential and effective therapeutic approach
to cure COVID19 infection and its pathological consequences, requiring further validation in large
cohort patient-derived samples.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/12/6/614/s1.
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of geographically different SARS-CoV-2 and other coronaviruses. Figure S1. miR8067 structure is drawn with
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